End-point interpretation in clinical trials: the case for discipline.

[1]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[2]  D. DeMets,et al.  Fundamentals of Clinical Trials , 1982 .

[3]  N L Geller,et al.  The analysis of multiple endpoints in clinical trials. , 1987, Biometrics.

[4]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[5]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[6]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[7]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[8]  J A Lewis,et al.  Statistical issues in the regulation of medicines. , 1995, Statistics in medicine.

[9]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[10]  L A Moyé,et al.  P-value interpretation and alpha allocation in clinical trials. , 1998, Annals of epidemiology.

[11]  L. Fisher.  Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. , 1999, Controlled clinical trials.